---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-22-000039"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:50:30.641590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023

## Summary
- Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.
- Cash and marketable securities $226.6M at Sep 30, 2022; runway into at least 2026.
- FDA accepted TP-03 NDA for Demodex blepharitis; PDUFA target action date Aug 25, 2023.
- Board changes: Scott Morrison appointed Audit Chair; Chairman Ackermann to depart; CEO Azamian expected to become Chairman.
- Expected $30M milestones from LianBio out-license: $10M Dec 2022, $5M Q1 2023.

## SEC filing metadata
- accession: 0001819790-22-000039
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/tars-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-22-000039
- JSON: https://secwatch.observer/filing/0001819790-22-000039.json
- Plain text: https://secwatch.observer/filing/0001819790-22-000039.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $0
  - Net income: $22.5 million
  - Result: reported results
  source text: to net loss of $15.7 million for the same period in 2021 • Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0, compared to $1.2 million for the same period in 2021 • Third quarter research and development expenses for 2022 were $10.9 million (inclusive of stock-based compensation of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $0
  - Net income: $22.5 million
  - Result: reported results
  source text: Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.